German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT)

The National Center for Tumor Diseases – NCT Heidelberg was founded as an exceptional alliance between the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKL-HD), the Heidelberg Medical Faculty, and German Cancer Aid (Deutsche Krebshilfe).


About us

The German Cancer Research Center (DKFZ) is the largest biomedical research center in Germany (staff: 3000). Established in 1964, DKFZ pursues the mission to unravel cancer causes and mechanisms. In addition to its excellence in basic science, DKFZ has a track record of outstanding translational research, since 2005 consolidated into its dedicated clinical translation center - the National Center for Tumor Diseases (NCT) - in collaboration with the Heidelberg University Hospital together with the Heidelberg Medical Faculty and German Cancer Aid (Deutsche Krebshilfe).

 

DKFZ NCT Combined

 

The NCT provides infrastructure and resources that integrate and support all of DKFZ’s and HUMS’s clinical and translational cancer research activities. DKFZ provides NCT with full access to its excellent research infrastructure and resources.Established in 1964, DKFZ is the largest biomedical research center in Germany (staff: 3000). Research activities concentrate on basic cancer research, disease modeling, and translational cancer research. DKFZ is an international leader in the areas of brain tumors, genome-based molecular stratification, and innovative radiation oncology. UKL-HD is one of the largest and most prestigious medical centers in Europe (11,768 staff). The highest standards of medical care are guaranteed by world-renowned professors, distinguished physicians and committed nursing staff. Heidelberg University Hospital is constantly developing new methods of diagnosis and treatment at the forefront of biomedical science for the benefit of all patients. AT NCT patient numbers are steadily growing and various therapeutic and preventive clinical trials, including investigator initiated trials, are developed and conducted.

A focus on precision oncology

NCT Heidelberg has implemented a Precision Oncology Program (NCT POP) as a center-wide master strategy. NCT POP focuses all translational activities towards individualized cancer medicine, including patient-oriented strategies in genomics, proteomics, immunology, radiooncology, prevention, and early clinical development. To this end, DKFZ has established the Heidelberg center for Personalized Oncology (DKFZ-HIPO), a dedicated genomics, proteomics and bioinformatics platform harboring the largest genome sequencing core in Germany (Illumina HiSeq X-Ten facility).

Patient stratification for treatment strategies

Towards molecular stratification, the NCT MASTER (Molecularly Aided Stratification for Tumor Eradication) umbrella protocol provides a clinical implementation workflow for high-throughput diagnostics. Steps include: quality-assured sample acquisition; histopathological evaluation; quality-managed analyte extraction; NGS and other “omics” technologies; bioinformatic processing; GLP-certified validation of variants; and clinical evaluation by a molecular tumor board. NCT MASTER makes it possible to perform and evaluate molecular diagnostics on materials from all consenting NCT patients, with the explicit purpose of stratifying each patient for the best treatment or trial strategy. In order to best integrate and exploit the data produced in all NCT programs, a central NCT DataThereHouse contains a working copy of every patient-related dataset from all IT sources to enable efficient retrieval, aggregation, and evaluation of molecular and clinical data for clinical decision making and translational research.

Clinical cancer programs and trials

Multiple Clinical Cancer Programs with clinical and scientific excellence organize interdisciplinary patient care and form disease-oriented coordinated research programs that link NCT, DKFZ, and HUMS research groups with national and international research and clinical trial networks. Focus programs for neurooncology, gastrointestinal tumors, multiple myeloma, pediatric tumors, lung cancer, among others, use campus-wide high-quality scientific and technical platforms to advance the clinical translation of basic research into clinical application. The NCT Radiation Oncology Program has a strong link to all NCT Clinical Cancer Programs and provides a platform for the early development of new radiation oncology techniques (such as the Heidelberg Ion Therapy Unit (HIT)) towards precision oncology.

Current trials include the Heidelberg-led INFORM study, which enrolls all children and adolescents with relapsed or refractory cancers in Germany for comprehensive molecular profiling. The NCT MASTER MATCH trial focuses on rare tumors and adult patients – at NCT and DKTK sites - with systemic cancers who are younger than 50 years. The NCT Neuro MASTER MATCH trial uses obligatory genome-wide methylation analyses and a glioma gene panel to treat newly diagnosed glioma as a paradigm for other entities.

In addition to activities at the center, numerous model projects for precision oncology are moving forward in interaction with the German Consortium for Translational Cancer Research (DKTK), the National Cohort, and the Helmholtz initiative on Personalized Medicine (iMed). In line with the Cancer Core Europe consortium, it is NCT’s overall aim to provide optimal individualization of treatment decisions according to the specific needs of each individual patient by reaching across traditional disciplines and academic departments. 

Publications

  • Sturm D et al. New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs, Cell 2016
  • Noll EM et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma, Nat. Med. 2016
  • Ruggiero E et al. High-resolution analysis of the human T-cell receptor repertoire, Nat. Commun. 2015
  • Hovestadt V et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing, Nature 2014
  • Wick et al. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma, Clin Cancer Res 2014
  • Dietrich S et al. Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia, J Clin Oncol 2013
  • Jäger N et al. Hypermutation of the Inactive X Chromosome Is a Frequent Event in Cancer, Cell 2013
  • Dietrich S, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012
  • Jones DT et al. Dissecting the genomic complexity underlying medulloblastoma, Nature 2012

Coordination Officer

Dr. Elisabeth Fischermeier
NCT Heidelberg
Im Neuenheimer Feld 460
D-69120 Heidelberg
Phone:  +49 (0) 6221 56-6794
E-Mail:  elisabeth.fischermeier@nct-heidelberg.de
 

Leadership team

Michael Baumann
 

Michael Baumann, MD, PhD is Chairman and Scientific Director of the Management Board of the German Cancer Research Center (DKFZ).

Christof von Kalle
 

Christof von Kalle, MD, PhD is Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg, and has been since 2005.

 
Dirk Jäger
 

Dirk Jäger, MD, is Director of the NCT as well as of the Department of Medical Oncology at the Heidelberg University Hospital, and head of the Clinical Cooperation Unit Applied Tumor Immunity at the DKFZ

 

Location map